IL188151A0 - ANTIBODIES THAT BIND TO HUMAN PDGFRd AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME - Google Patents

ANTIBODIES THAT BIND TO HUMAN PDGFRd AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME

Info

Publication number
IL188151A0
IL188151A0 IL188151A IL18815107A IL188151A0 IL 188151 A0 IL188151 A0 IL 188151A0 IL 188151 A IL188151 A IL 188151A IL 18815107 A IL18815107 A IL 18815107A IL 188151 A0 IL188151 A0 IL 188151A0
Authority
IL
Israel
Prior art keywords
pdgfrd
antibodies
bind
human
same
Prior art date
Application number
IL188151A
Other languages
English (en)
Original Assignee
Imclone Systems Inc
Univ Washington
Drexel University College Of M
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imclone Systems Inc, Univ Washington, Drexel University College Of M filed Critical Imclone Systems Inc
Publication of IL188151A0 publication Critical patent/IL188151A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Reproductive Health (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL188151A 2005-06-17 2007-12-16 ANTIBODIES THAT BIND TO HUMAN PDGFRd AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME IL188151A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US69192005P 2005-06-17 2005-06-17
PCT/US2006/023856 WO2006138729A2 (en) 2005-06-17 2006-06-19 Receptor antagonists for treatment of metastatic bone cancer

Publications (1)

Publication Number Publication Date
IL188151A0 true IL188151A0 (en) 2008-03-20

Family

ID=37571297

Family Applications (3)

Application Number Title Priority Date Filing Date
IL188151A IL188151A0 (en) 2005-06-17 2007-12-16 ANTIBODIES THAT BIND TO HUMAN PDGFRd AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
IL198870A IL198870A (en) 2005-06-17 2009-05-21 ISOLATED ANTIBODIES OR FRAGMENTS THEREOF SPECIFIC FOR HUMAN PDGFRa, ISOLATED POLYNUCLEIC ACID COMPRISING NUCLEOTIDE SEQUENCE ENCODING SAID ANTIBODIES, EXPRESSION VECTOR COMPRISING SAID POLYNUCLEIC ACID AND RECOMBINANT CELL COMPRISING SAID EXPRESSION VECTOR
IL198869A IL198869A (en) 2005-06-17 2009-05-21 Anti-human pdgfr-alpha antibody for use in the treatment of secondary bone tumors

Family Applications After (2)

Application Number Title Priority Date Filing Date
IL198870A IL198870A (en) 2005-06-17 2009-05-21 ISOLATED ANTIBODIES OR FRAGMENTS THEREOF SPECIFIC FOR HUMAN PDGFRa, ISOLATED POLYNUCLEIC ACID COMPRISING NUCLEOTIDE SEQUENCE ENCODING SAID ANTIBODIES, EXPRESSION VECTOR COMPRISING SAID POLYNUCLEIC ACID AND RECOMBINANT CELL COMPRISING SAID EXPRESSION VECTOR
IL198869A IL198869A (en) 2005-06-17 2009-05-21 Anti-human pdgfr-alpha antibody for use in the treatment of secondary bone tumors

Country Status (21)

Country Link
US (3) US8128929B2 (member.php)
EP (4) EP1909819A4 (member.php)
JP (4) JP2009501141A (member.php)
KR (3) KR20080047529A (member.php)
CN (3) CN101500597A (member.php)
BE (1) BE2017C007I2 (member.php)
BR (2) BRPI0611984A2 (member.php)
CA (3) CA2680945C (member.php)
CY (3) CY1114603T1 (member.php)
DK (2) DK2100618T3 (member.php)
ES (2) ES2435727T3 (member.php)
HU (1) HUS1700015I1 (member.php)
IL (3) IL188151A0 (member.php)
LT (1) LTC2100614I2 (member.php)
LU (1) LUC00012I2 (member.php)
NL (1) NL300869I2 (member.php)
PL (2) PL2100614T3 (member.php)
PT (2) PT2100614E (member.php)
RU (3) RU2502523C2 (member.php)
SI (2) SI2100614T1 (member.php)
WO (1) WO2006138729A2 (member.php)

Families Citing this family (122)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2100618T3 (en) * 2005-06-17 2014-03-03 Imclone Llc Anti-PDGFR alpha antibody for use in the treatment of metastatic bone cancer
EP1984011A4 (en) * 2006-02-03 2010-08-18 Imclone Llc IGF-IR ANTAGONISTS AS AUXILIARIES FOR THE TREATMENT OF PROSTATE CANCER
CL2007002225A1 (es) 2006-08-03 2008-04-18 Astrazeneca Ab Agente de union especifico para un receptor del factor de crecimiento derivado de plaquetas (pdgfr-alfa); molecula de acido nucleico que lo codifica; vector y celula huesped que la comprenden; conjugado que comprende al agente; y uso del agente de un
CL2008001071A1 (es) * 2007-04-17 2009-05-22 Smithkline Beecham Corp Metodo para obtener anticuerpo penta-especifico contra il-8/cxcl8, gro-alfa/cxcl1, gro-beta/cxcl2), gro-gama/cxcl3 y ena-78/cxcl5 humanas; anticuerpo penta-especifico; proceso de produccion del mismo; vector, hbridoma o celela que lo comprende; composicion farmceutica; uso para tratar copd, otras enfermedades.
US8435510B2 (en) * 2007-08-08 2013-05-07 Sutter West Bay Hospitals Platelet derived growth factor receptor supports cytomegalovirus infectivity
AU2008304111B2 (en) 2007-09-27 2014-04-24 Amgen Inc. Pharmaceutical formulations
ES2962777T3 (es) 2007-11-15 2024-03-21 Amgen Inc Formulación acuosa de anticuerpos estabilizada por antioxidantes para la administración parenteral
US20090280112A1 (en) * 2008-05-05 2009-11-12 The Regents Of The University Of California Inhibitory effects of nordihydroguaiaretic acid (ndga) on the igf-1 receptor and androgen dependent growth of lapc-4 prostate cancer cells
TW201000119A (en) * 2008-06-10 2010-01-01 Oncotherapy Science Inc MYBL2 epitope peptides and vaccines containing the same
MX344382B (es) 2009-10-23 2016-12-14 Amgen Inc * Adaptador de vial y sistema.
SG194370A1 (en) 2010-06-07 2013-11-29 Amgen Inc Drug delivery device
JP2013177317A (ja) * 2010-06-24 2013-09-09 Meneki Seibutsu Kenkyusho:Kk 抗ｐｄｇｆ受容体抗体
CA2803998A1 (en) 2010-07-02 2012-01-05 Medimmune, Llc Antibody formulations
MX2013008833A (es) 2011-02-02 2013-12-06 Amgen Inc Metodos y composiciones relacionadas con la inhibicion de receptor del factor de crecimiento similar a la insulina 1 (igf-1r).
US9480624B2 (en) 2011-03-31 2016-11-01 Amgen Inc. Vial adapter and system
EP4074355A1 (en) 2011-04-20 2022-10-19 Amgen Inc. Autoinjector apparatus
HK1199883A1 (en) 2011-08-26 2015-07-24 Merrimack Pharmaceuticals, Inc. Tandem fc bispecific antibodies
US9987428B2 (en) 2011-10-14 2018-06-05 Amgen Inc. Injector and method of assembly
US9700619B2 (en) 2011-11-11 2017-07-11 Duke University Combination drug therapy for the treatment of solid tumors
US8980259B2 (en) 2012-07-20 2015-03-17 Novartis Ag Combination therapy
ES2860954T3 (es) 2012-11-21 2021-10-05 Amgen Inc Dispositivo de administración de fármacos
JP6255038B2 (ja) 2013-02-26 2017-12-27 トリアクト セラピューティクス，インク． 癌治療
EA201591652A1 (ru) 2013-03-06 2016-02-29 Мерримак Фармасьютикалз, Инк. ТАНДЕМНЫЕ БИСПЕЦИФИЧЕСКИЕ Fc-АНТИТЕЛА ПРОТИВ c-MET
TWI592183B (zh) 2013-03-15 2017-07-21 安美基公司 本體輪廓可調適之自動注射器裝置
TWI580452B (zh) 2013-03-15 2017-05-01 安美基公司 用於注射器之匣盒、注射器及使用包括自動注射器及匣盒之設備之方法
CA2904725C (en) 2013-03-15 2022-04-12 Amgen Inc. Drug cassette, autoinjector, and autoinjector system
US10850037B2 (en) 2013-03-22 2020-12-01 Amgen Inc. Injector and method of assembly
US9381246B2 (en) 2013-09-09 2016-07-05 Triact Therapeutics, Inc. Cancer therapy
BR112016008946B1 (pt) 2013-10-24 2022-12-27 Amgen Inc Injetores e método para montar os injetor
WO2015061389A1 (en) 2013-10-24 2015-04-30 Amgen Inc. Drug delivery system with temperature-sensitive control
CN106029150B (zh) * 2013-12-20 2020-01-14 波士顿科学国际有限公司 集成导管系统
US10994112B2 (en) 2014-02-05 2021-05-04 Amgen Inc. Drug delivery system with electromagnetic field generator
WO2015171777A1 (en) 2014-05-07 2015-11-12 Amgen Inc. Autoinjector with shock reducing elements
KR102710533B1 (ko) 2014-06-03 2024-09-26 암겐 인코포레이티드 제어 가능한 약물 전달 시스템 및 사용 방법
WO2016003789A1 (en) * 2014-07-03 2016-01-07 Imclone Llc Combination therapy
MX2016016866A (es) * 2014-07-03 2017-04-25 Imclone Llc Terapia para gist.
EP3943135B1 (en) 2014-10-14 2025-09-24 Amgen Inc. Drug injection device with visual and audible indicators
CA2965960A1 (en) 2014-10-27 2016-05-06 Agency For Science, Technology And Research Anti-tim-3 antibodies
GB201419084D0 (en) 2014-10-27 2014-12-10 Agency Science Tech & Res Anti-PD-1 antibodies
GB201419094D0 (en) 2014-10-27 2014-12-10 Agency Science Tech & Res Anti-TIM-3-antibodies
EP3233163B1 (en) 2014-12-19 2021-10-13 Amgen Inc. Drug delivery device with proximity sensor
ES2785311T3 (es) 2014-12-19 2020-10-06 Amgen Inc Dispositivo de administración de fármacos con botón móvil o campo de interfaz de usuario
CA3069716C (en) 2015-02-17 2021-11-09 Amgen Inc. Drug delivery device with vacuum assisted securement and/or feedback
US11806509B2 (en) 2015-02-27 2023-11-07 Amgen Inc. Drug delivery device having a needle guard mechanism with a turnable threshold of resistance to needle guard movement
WO2017039786A1 (en) 2015-09-02 2017-03-09 Amgen Inc. Syringe assembly adapter for a syringe
JP7082568B2 (ja) 2015-12-09 2022-06-08 アムジエン・インコーポレーテツド 信号伝達キャップ付き自動注射器
EA202192290A1 (ru) 2015-12-16 2022-02-28 Ридженерон Фармасьютикалз, Инк. Композиции и способы получения белковых микрочастиц
WO2017120178A1 (en) 2016-01-06 2017-07-13 Amgen Inc. Auto-injector with signaling electronics
DK3429663T3 (da) 2016-03-15 2020-09-28 Amgen Inc Reduktion af sandsynligheden for glasbrud i anordninger til indgivelse af lægemidler
WO2017189089A1 (en) 2016-04-29 2017-11-02 Amgen Inc. Drug delivery device with messaging label
WO2017192287A1 (en) 2016-05-02 2017-11-09 Amgen Inc. Syringe adapter and guide for filling an on-body injector
ES2959783T3 (es) 2016-05-13 2024-02-28 Amgen Inc Conjunto de cubierta protectora de vial
EP3458988B1 (en) 2016-05-16 2023-10-18 Amgen Inc. Data encryption in medical devices with limited computational capability
US11541176B2 (en) 2016-06-03 2023-01-03 Amgen Inc. Impact testing apparatuses and methods for drug delivery devices
MA45493A (fr) 2016-06-27 2019-05-01 Aicuris Anti Infective Cures Gmbh Inhibiteurs d'entrée de hcmv.
EP3478342B1 (en) 2016-07-01 2025-03-12 Amgen Inc. Drug delivery device having minimized risk of component fracture upon impact events
WO2018022407A1 (en) * 2016-07-28 2018-02-01 Eli Lilly And Company Anti-canine platelet derived growth factor receptor alpha antibody
WO2018034784A1 (en) 2016-08-17 2018-02-22 Amgen Inc. Drug delivery device with placement detection
US20200261643A1 (en) 2016-10-25 2020-08-20 Amgen Inc. On-body injector
KR102014066B1 (ko) 2017-01-06 2019-10-21 에이비엘바이오 주식회사 항 α-syn 항체 및 그 용도
AU2018210301A1 (en) 2017-01-17 2019-08-01 Amgen Inc. Injection devices and related methods of use and assembly
EP3582825A1 (en) 2017-02-17 2019-12-25 Amgen Inc. Drug delivery device with sterile fluid flowpath and related method of assembly
US11369736B2 (en) 2017-02-17 2022-06-28 Amgen Inc. Cannula insertion and retraction mechanisms
WO2018165143A1 (en) 2017-03-06 2018-09-13 Amgen Inc. Drug delivery device with activation prevention feature
EP3592402A1 (en) 2017-03-07 2020-01-15 Amgen Inc. Needle insertion by overpressure
KR102619150B1 (ko) 2017-03-09 2023-12-27 암겐 인코포레이티드 약물 전달 장치용 삽입 메커니즘
US20200071415A1 (en) 2017-03-17 2020-03-05 Imclone Llc Combination therapy for pancreatic cancer
DK3600491T3 (da) 2017-03-28 2023-10-23 Amgen Inc Stempelstang og sprøjtekonstruktionssystem samt fremgangsmåde
WO2018226565A1 (en) 2017-06-08 2018-12-13 Amgen Inc. Torque driven drug delivery device
EP3634539A1 (en) 2017-06-08 2020-04-15 Amgen Inc. Syringe assembly for a drug delivery device and method of assembly
CA3063920A1 (en) 2017-06-22 2018-12-27 Amgen Inc. Device activation impact/shock reduction
WO2018237225A1 (en) 2017-06-23 2018-12-27 Amgen Inc. Electronic drug delivery device comprising a cap activated by a switch assembly
IL270784B2 (en) 2017-07-14 2023-11-01 Amgen Inc Needle insertion-extraction system with a double torsion spring system
JP7649105B2 (ja) 2017-07-21 2025-03-19 アムジエン・インコーポレーテツド 薬物容器のためのガス透過性シーリング部材及び組立方法
EP4085942A1 (en) 2017-07-25 2022-11-09 Amgen Inc. Drug delivery device with gear module and related method of assembly
JP7242562B2 (ja) 2017-07-25 2023-03-20 アムジエン・インコーポレーテツド 容器アクセスシステムを有する薬物送達デバイス及び関連する組立方法
EP3664863A2 (en) 2017-08-09 2020-06-17 Amgen Inc. Hydraulic-pneumatic pressurized chamber drug delivery system
EP3668567B1 (en) 2017-08-18 2026-02-18 Amgen Inc. Wearable injector with sterile adhesive patch
US11103636B2 (en) 2017-08-22 2021-08-31 Amgen Inc. Needle insertion mechanism for drug delivery device
WO2019070472A1 (en) 2017-10-04 2019-04-11 Amgen Inc. FLOW ADAPTER FOR MEDICATION DELIVERY DEVICE
WO2019070497A1 (en) 2017-10-04 2019-04-11 Imclone Llc POLY THERAPY AGAINST CANCER
IL272636B2 (en) 2017-10-06 2024-10-01 Amgen Inc Drug delivery device with interlock assembly and related method of assembly
ES3055487T3 (en) 2017-10-09 2026-02-12 Amgen Inc Drug delivery device with drive assembly and related method of assembly
MA50528A (fr) 2017-11-03 2020-09-09 Amgen Inc Systèmes et approches pour stériliser un dispositif d'administration de médicament
MA50569A (fr) 2017-11-06 2020-09-16 Amgen Inc Ensembles de remplissage-finition et procédés associés
US20200261648A1 (en) 2017-11-06 2020-08-20 Amgen Inc. Drug delivery device with placement and flow sensing
JP7247174B2 (ja) 2017-11-10 2023-03-28 アムジエン・インコーポレーテツド 薬物送達デバイスのプランジャ
MA50904A (fr) 2017-11-16 2020-09-23 Amgen Inc Mécanisme d'insertion d'aiguille pour dispositif d'administration de médicament
MA50903A (fr) 2017-11-16 2021-05-12 Amgen Inc Auto-injecteur avec détection de décrochage et de point d'extrémité
WO2019117684A1 (ko) 2017-12-14 2019-06-20 에이비엘바이오 주식회사 a-syn/IGF1R에 대한 이중 특이 항체 및 그 용도
US10835685B2 (en) 2018-05-30 2020-11-17 Amgen Inc. Thermal spring release mechanism for a drug delivery device
WO2019231803A1 (en) 2018-05-31 2019-12-05 Imclone Llc Combination therapy for soft tissue sarcoma
US11083840B2 (en) 2018-06-01 2021-08-10 Amgen Inc. Modular fluid path assemblies for drug delivery devices
US12115360B2 (en) 2018-07-24 2024-10-15 Amgen Inc. Hybrid drug delivery devices with grip portion
CA3103681A1 (en) 2018-07-24 2020-01-30 Amgen Inc. Delivery devices for administering drugs
WO2020023220A1 (en) 2018-07-24 2020-01-30 Amgen Inc. Hybrid drug delivery devices with tacky skin attachment portion and related method of preparation
CN112351804A (zh) 2018-07-24 2021-02-09 安进公司 用于施用药物的输送装置
WO2020028009A1 (en) 2018-07-31 2020-02-06 Amgen Inc. Fluid path assembly for a drug delivery device
JP2022500095A (ja) 2018-09-24 2022-01-04 アムジエン・インコーポレーテツド インターベンション投薬システム及び方法
AU2019350660B2 (en) 2018-09-28 2024-09-26 Amgen Inc. Muscle wire escapement activation assembly for a drug delivery device
TWI857975B (zh) 2018-10-02 2024-10-11 美商安進公司 具有內部力傳遞的用於藥物遞送之注射系統
AR116607A1 (es) 2018-10-05 2021-05-26 Amgen Inc Dispositivo de administración de fármacos con indicador de dosis
AU2019359801B2 (en) 2018-10-15 2025-01-02 Amgen Inc. Platform assembly process for drug delivery device
KR102848295B1 (ko) 2018-10-15 2025-08-20 암젠 인크 댐핑 메커니즘을 갖는 약물 전달 장치
IL281908B2 (en) 2018-11-01 2025-06-01 Amgen Inc Drug delivery devices with partial drug delivery member retraction
TWI831847B (zh) 2018-11-01 2024-02-11 美商安進公司 部分針頭縮回之藥物遞送裝置及其操作方法
MA54048A (fr) 2018-11-01 2022-02-09 Amgen Inc Dispositifs d'administration de médicament avec rétraction partielle de l'organe d'administration de médicament
EP3883610A4 (en) 2018-11-20 2022-11-02 Cornell University MACROCYCLIC COMPLEXES OF RADIONUCLIDES AND THEIR USE IN CANCER RADIATION THERAPY
CN109134655B (zh) * 2018-11-28 2019-02-26 上海复宏汉霖生物技术股份有限公司 一种抗PDGFRα的单克隆抗体及其制备方法和应用
EP3958934B1 (en) 2019-04-24 2025-04-09 Amgen Inc. Syringe sterilization verification assemblies and methods
MX2022002149A (es) 2019-08-23 2022-03-17 Amgen Inc Dispositivo de suministro de farmacos con componentes de acoplamiento de capuchon de aguja configurable y metodos relacionados.
KR20220054689A (ko) 2019-10-15 2022-05-03 일라이 릴리 앤드 캄파니 재조합적으로 조작된, 리파제/에스테라제-결핍 포유동물 세포주
JP7769388B2 (ja) 2019-12-12 2025-11-13 ティン セラピューティクス，インコーポレイテッド 聴覚損失の予防及び治療のための組成物及び方法
CA3210922A1 (en) * 2021-03-19 2022-09-22 Gerard Joseph OAKLEY III Methods of treating cancer with pdgfr alpha inhibitors
JP2024523779A (ja) 2021-05-21 2024-07-02 アムジェン インコーポレイテッド 薬物容器用の充填レシピを最適化する方法
AU2022379973A1 (en) 2021-11-08 2024-06-27 Progentos Therapeutics, Inc. Platelet-derived growth factor receptor (pdgfr) alpha inhibitors and uses thereof
WO2024207069A1 (en) * 2023-04-04 2024-10-10 Telix Pharmaceuticals (Innovations) Pty Ltd Reagents and methods for imaging cancers expressing pdgfralpha
EP4688007A1 (en) * 2023-04-04 2026-02-11 Telix Pharmaceuticals (Innovations) Pty Ltd Methods of treating cancers expressing pdgfralpha
AU2023442603A1 (en) * 2023-04-04 2025-09-11 Eli Lilly And Company Reagents and methods for imaging cancers expressing pdgfralpha
WO2024207070A1 (en) * 2023-04-04 2024-10-10 Telix Pharmaceuticals (Innovations) Pty Ltd Methods of treating cancers expressing pdgfralpha
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof
WO2026030152A1 (en) 2024-07-29 2026-02-05 Amgen Inc. System and method for assessing transferability of a fill recipe

Family Cites Families (108)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5585344A (en) 1984-03-19 1996-12-17 The Rockefeller University Liver-derived receptors for advanced glycosylation endproducts and uses thereof
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4774321A (en) 1986-12-01 1988-09-27 Massachusetts Institute Of Technology DP100 EGF and insulin-binding protein from Drosophila cells
US5200509A (en) 1987-04-06 1993-04-06 Celtrix Pharmaceuticals, Inc. Human somatomedin carrier protein subunits and process for producing them; recombinant DNA molecules, hosts, processes and human somatomedin carrier protein-like polypeptides
EP0308500B1 (en) 1987-04-06 1993-06-16 Celtrix Pharmaceuticals, Inc. Human somatomedin carrier protein subunits and process for producing them
JP3040121B2 (ja) 1988-01-12 2000-05-08 ジェネンテク，インコーポレイテッド 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
IL89489A0 (en) 1988-03-09 1989-09-10 Hybritech Inc Chimeric antibodies directed against human carcinoembryonic antigen
JPH02503867A (ja) 1988-04-15 1990-11-15 プロテイン　デザイン　ラブズ　インコーポレーテッド Ｉｌ‐２レセプター特異的キメラ抗体
JP3105898B2 (ja) 1988-04-16 2000-11-06 セルテック リミテッド 組換えｄｎａタンパクの製造方法
AU4128089A (en) 1988-09-15 1990-03-22 Rorer International (Overseas) Inc. Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same
GB8826451D0 (en) 1988-11-11 1988-12-14 Sandoz Ltd Improvements in/relating to organic compounds
US5571714A (en) 1988-12-22 1996-11-05 Celtrix Pharmaceuticals, Inc. Monoclonal antibodies which bind both transforming growth factors β1 and β2 and methods of use
IL92816A0 (en) 1988-12-22 1990-09-17 Biogrowth Inc Recombinant dna molecules,hosts,processes and human somatomedin carrier protein-like polypeptides
ATE397659T1 (de) 1989-02-09 2008-06-15 Us Health Polyklonale antikörper gegen den menschlichen alpha-pdgf-rezeptor und dessen verwendung
US5468468A (en) 1989-02-09 1995-11-21 The United States Of America, As Represented By The Secretary Of The Department Of Health & Human Services Method for making a monoclonal antibody, monoclonal antibodies to α PD
US7252929B2 (en) 1989-02-09 2007-08-07 United States Of America, As Represented By The Secretary, Dept Of Health & Human Services Methods for identifying alpha PDGFR agonists and antagonists
US6228600B1 (en) 1992-07-20 2001-05-08 The United States Of America As Represented By The Department Of Health And Human Services Immunoassays for the alpha platelet-derived growth factor receptor
US5705157A (en) 1989-07-27 1998-01-06 The Trustees Of The University Of Pennsylvania Methods of treating cancerous cells with anti-receptor antibodies
US5977307A (en) 1989-09-07 1999-11-02 Alkermes, Inc. Transferrin receptor specific ligand-neuropharmaceutical agent fusion proteins
US5196446A (en) 1990-04-16 1993-03-23 Yissum Research Development Company Of The Hebrew University Of Jerusalem Certain indole compounds which inhibit EGF receptor tyrosine kinase
IL97872A (en) 1990-04-16 1996-07-23 Rhone Poulenc Rorer Int Pharmaceutical compositions containing styryl-substituted monocylic and bicyclic heteroaryl compounds which inhibit egf receptor tyrosine kinase and a compounds of this type
PT98803B (pt) 1990-08-28 1999-01-29 Chiron Corp Processo de preparacao de uma proteina de ligacao purificada
CA2100559C (en) 1991-01-31 2007-05-22 David Wolf Domains of extracellular region of human platelet derived growth factor receptor polypeptides
GB9300059D0 (en) 1992-01-20 1993-03-03 Zeneca Ltd Quinazoline derivatives
US5262308A (en) 1992-01-28 1993-11-16 Thomas Jefferson University Cell lines which constitutively express IGF-1 and IGF-1 R
WO1993021319A1 (en) 1992-04-08 1993-10-28 Cetus Oncology Corporation HUMANIZED C-erbB-2 SPECIFIC ANTIBODIES
US5597563A (en) 1992-09-04 1997-01-28 Beschorner; William E. Method induction of antigen-specific immune tolerance
US5869337A (en) 1993-02-12 1999-02-09 President And Fellows Of Harvard College Regulated transcription of targeted genes and other biological events
CA2156825C (en) 1993-02-25 2003-10-21 Charles E. Hart Inhibition of intimal hyperplasia using antibodies to pdgf receptors
US5976534A (en) 1993-02-25 1999-11-02 Zymogenetics, Inc. Inhibition of intimal hyperplasia using antibodies to PDGF receptors and heparin
US5620687A (en) 1993-02-25 1997-04-15 Zymogenetics, Inc. Inhibition of intimal hyperplasia using antibodies to PDGF beta receptors
EP0694069A1 (en) 1993-04-06 1996-01-31 Cedars-Sinai Medical Center Variant insulin-like growth factor i receptor subunits and methods for use thereof
WO1995019570A1 (en) 1994-01-14 1995-07-20 Genentech, Inc. Antagonists to insulin receptor tyrosine kinase inhibitor
US5679683A (en) 1994-01-25 1997-10-21 Warner-Lambert Company Tricyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family
US5532159A (en) 1994-04-01 1996-07-02 The Ohio State University Monoclonal antibody to canine placental oncofetal protein for detecting cancer
US5597700A (en) 1994-04-28 1997-01-28 California Research, Llc Method for detecting free insulin-like growth-factor-binding protein 1 and a test device for detecting the ruptures of fetal membranes using the above method
WO1996000084A1 (en) 1994-06-24 1996-01-04 Torchilin Vladimir P Use of autoantibodies for tumor therapy and prophylaxis
US5939269A (en) 1994-12-28 1999-08-17 The Regents Of The University Of California Antagonists to insulin receptor tyrosine kinase inhibitor
PT817775E (pt) 1995-03-30 2002-01-30 Pfizer Derivados de quinazolina
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
EP0861267A4 (en) 1995-11-14 2000-02-02 Univ Jefferson INDUCTION AND RESISTANCE TO TUMOR GROWTH BY MEANS OF SOLUBLE IGF-1
ATE217873T1 (de) 1996-01-23 2002-06-15 Novartis Erfind Verwalt Gmbh Pyrrolopyrimidinen und verfahren zu deren herstellung
GB9603095D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
GB9707800D0 (en) 1996-05-06 1997-06-04 Zeneca Ltd Chemical compounds
AUPN999096A0 (en) 1996-05-22 1996-06-13 Northstar Biologicals Pty Ltd Peptides, antibodies, vaccines & uses thereof
ATE308527T1 (de) 1996-06-24 2005-11-15 Pfizer Phenylamino-substituierte triicyclische derivate zur behandlung hyperproliferativer krankheiten
US5798266A (en) 1996-08-27 1998-08-25 K-Quay Enterprises, Llc Methods and kits for obtaining and assaying mammary fluid samples for breast diseases, including cancer
US6071891A (en) 1996-11-22 2000-06-06 Regents Of The University Of Minnesota Insulin-like growth factor 1 receptors (IGF-1R) antisense oligonucleotide cells composition
KR20000070751A (ko) 1997-02-05 2000-11-25 로즈 암스트롱, 크리스틴 에이. 트러트웨인 세포 증식 억제제로서의 피리도[2,3-ｄ]피리미딘 및 4-아미노피리미딘
JP2002515511A (ja) 1998-05-15 2002-05-28 イムクローン システムズ インコーポレイティド 放射線及び成長因子レセプター・チロシン・キナーゼのインヒビターを使用するヒト腫瘍の治療
ZA200007412B (en) 1998-05-15 2002-03-12 Imclone Systems Inc Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases.
US6875741B2 (en) 1998-09-02 2005-04-05 Renuka Pillutla Insulin and IGF-1 receptor agonists and antagonists
CZ303899B6 (cs) 1998-09-29 2013-06-19 Wyeth Holdings Corporation Substituovaný 3-kyanochinolin, zpusob jeho prípravy a farmaceutická kompozice s jeho obsahem
EP1117421B2 (en) 1998-10-05 2014-03-19 Bavarian Nordic Inc. Methods for therapeutic vaccination
NZ512189A (en) 1998-11-19 2003-10-31 Warner Lambert Co N-[4-(3-chloro-4-fluoro-phenylamino)-7-(3-morpholin-4- yl-propoxy)-quinazolin-6-yl]-acrylamide useful as an irreversible inhibitor of tyrosine kinases
EP1006184A1 (en) 1998-12-03 2000-06-07 F. Hoffmann-La Roche Ag IGF-1 receptor interacting proteins (IIPs) genes coding therefor and uses thereof
US6316462B1 (en) 1999-04-09 2001-11-13 Schering Corporation Methods of inducing cancer cell death and tumor regression
CA2378365A1 (en) 1999-07-27 2001-02-01 Michael Miravet Sorribes A device for non-invasively correcting the shape of a human external ear
AU2001264946A1 (en) 2000-05-24 2001-12-03 Imclone Systems Incorporated Bispecific immunoglobulin-like antigen binding proteins and method of production
RU2183461C2 (ru) * 2000-05-29 2002-06-20 Ростовский научно-исследовательский онкологический институт МЗ РФ Способ лечения сарком мягких тканей
US20030165502A1 (en) 2000-06-13 2003-09-04 City Of Hope Single-chain antibodies against human insulin-like growth factor I receptor: expression, purification, and effect on tumor growth
US7329745B2 (en) 2000-06-13 2008-02-12 City Of Hope Single-chain antibodies against human insulin-like growth factor I receptor: expression, purification, and effect on tumor growth
US7071160B2 (en) 2000-06-15 2006-07-04 Kyowa Hakko Kogyo Co., Ltd. Insulin-like growth factor-binding protein
US8153121B2 (en) 2000-10-06 2012-04-10 Los Angeles Biomedical Research Institute at Harbor—UCLA Medical Center Diagnosis and therapy of antibody-mediated inflammatory autoimmune disorders
ME00502B (me) 2001-01-05 2011-10-10 Amgen Fremont Inc Antitjela za insulinu sličan receptor faktora i rasta
AU2002248609B2 (en) 2001-03-14 2007-03-01 Genentech, Inc. IGF antagonist peptides
WO2002087618A1 (en) 2001-04-27 2002-11-07 Takeda Chemical Industries, Ltd. Preventive/therapeutic method for cancer
US7135174B2 (en) * 2002-01-07 2006-11-14 Amgen Fremont, Inc. Antibodies directed to PDGFD and uses thereof
US7553485B2 (en) 2002-01-18 2009-06-30 Pierre Fabre Medicament Anti-IGF-IR and/or anti-insulin/IGF-I hybrid receptors antibodies and uses thereof
US7241444B2 (en) 2002-01-18 2007-07-10 Pierre Fabre Medicament Anti-IGF-IR antibodies and uses thereof
ES2283759T3 (es) 2002-01-18 2007-11-01 Pierre Fabre Medicament Anticuerpos anti-igf-ir y sus aplicaciones.
US7498414B2 (en) 2002-03-04 2009-03-03 Imclone Systems Incorporated Human antibodies specific to KDR and uses thereof
CN100422316C (zh) * 2002-05-24 2008-10-01 先灵公司 抗胰岛素样生长因子受体(igfr)的人源中和抗体
US8034904B2 (en) 2002-06-14 2011-10-11 Immunogen Inc. Anti-IGF-I receptor antibody
US7538195B2 (en) * 2002-06-14 2009-05-26 Immunogen Inc. Anti-IGF-I receptor antibody
DK1517921T3 (da) 2002-06-28 2006-10-09 Domantis Ltd Immunglobulin-enkeltvariable antigen-bindende domæner og dobbeltspecifikke konstruktioner deraf
CA2494310A1 (en) 2002-08-01 2004-02-12 Immunomedics, Inc. Alpha-fetoprotein immu31 antibodies and fusion proteins and methods of use thereof
US20040102360A1 (en) 2002-10-30 2004-05-27 Barnett Stanley F. Combination therapy
KR20050109489A (ko) 2003-02-13 2005-11-21 화이자 프로덕츠 인크. 항-인슐린양 성장인자 ｉ 수용체 항체의 용도
EP1603948A1 (en) 2003-03-14 2005-12-14 Pharmacia Corporation Antibodies to igf-i receptor for the treatment of cancers
CA2519113C (en) 2003-04-02 2012-06-05 F. Hoffmann-La Roche Ag Antibodies against insulin-like growth factor i receptor and uses thereof
WO2005016970A2 (en) 2003-05-01 2005-02-24 Imclone Systems Incorporated Fully human antibodies directed against the human insulin-like growth factor-1 receptor
RU2241452C1 (ru) * 2003-06-11 2004-12-10 Московский областной научно-исследовательский клинический институт Способ лечения метастазов в кости
AR046071A1 (es) 2003-07-10 2005-11-23 Hoffmann La Roche Anticuerpos contra el receptor i del factor de crecimiento de tipo insulinico y los usos de los mismos
JP4818917B2 (ja) 2003-08-08 2011-11-16 イミューノメディクス、インコーポレイテッド 腫瘍および罹患細胞のアポトーシスを誘発するための二重特異性抗体
EA200600234A1 (ru) * 2003-08-13 2006-08-25 Пфайзер Продактс Инк. Модифицированные igf - 1r антитела человека
JPWO2005018671A1 (ja) * 2003-08-21 2006-10-19 協和醗酵工業株式会社 癌転移阻害剤
WO2005027970A1 (ja) 2003-09-24 2005-03-31 Kyowa Hakko Kogyo Co., Ltd. 癌治療用医薬
PE20050928A1 (es) 2003-11-21 2005-11-08 Schering Corp Combinaciones terapeuticas de anticuerpo anti-igfr1
WO2005082415A2 (en) 2004-02-25 2005-09-09 Dana Farber Cancer Institute, Inc. Inhibitors of insulin-like growth factor receptor-1 for inhibiting tumor cell growth
DE602005027673D1 (de) * 2004-03-05 2011-06-09 Vegenics Pty Ltd Materialien und verfahren für wachstumsfaktorbindende konstrukte
JP4493485B2 (ja) 2004-04-28 2010-06-30 シャープ株式会社 太陽電池モジュール用配線部材、それを用いた太陽電池モジュールおよび太陽電池モジュール用配線部材の製造方法
EP2322217A3 (en) 2004-07-16 2011-09-28 Pfizer Products Inc. Combination treatment for non-hematologic malignancies using an anti-IGF-1R antibody
WO2006020258A2 (en) 2004-07-17 2006-02-23 Imclone Systems Incorporated Novel tetravalent bispecific antibody
FR2873699B1 (fr) 2004-07-29 2009-08-21 Pierre Fabre Medicament Sa Nouveaux anticorps anti igf ir rt leurs utilisations
ES2356830T3 (es) 2004-12-03 2011-04-13 Schering Corporation Biomarcadores para preselección de pacientes para terapia de anti-igf-1r.
WO2006068829A1 (en) 2004-12-21 2006-06-29 Alcon, Inc. Agents which regulate, inhibit, or modulate the activity and/or expression of lysyl oxidase (lox) and lox-like proteases as a unique means to both lower intraocular pressure and treat glaucomatous retinopathies/optic neuropathies
MY146381A (en) 2004-12-22 2012-08-15 Amgen Inc Compositions and methods relating relating to anti-igf-1 receptor antibodies
US20060233814A1 (en) 2005-04-15 2006-10-19 Immunogen Inc. Elimination of heterogeneous or mixed cell population in tumors
DK2100618T3 (en) * 2005-06-17 2014-03-03 Imclone Llc Anti-PDGFR alpha antibody for use in the treatment of metastatic bone cancer
WO2007000328A1 (en) 2005-06-27 2007-01-04 Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa Antibodies that bind to an epitope on insulin-like growth factor 1 receptor and uses thereof
US20070009970A1 (en) 2005-07-08 2007-01-11 Predicant Biosciences, Inc. Biological patterns for diagnosis and treatment of cancer
FR2888850B1 (fr) 2005-07-22 2013-01-11 Pf Medicament Nouveaux anticorps anti-igf-ir et leurs applications
JP5373396B2 (ja) 2005-08-26 2013-12-18 ロシュ グリクアート アクチェンゲゼルシャフト 改変された細胞シグナル活性有する改変抗原結合分子
KR101372690B1 (ko) 2005-12-13 2014-03-17 아스트라제네카 아베 인슐린 유사 성장 인자에 특이적인 결합 단백질 및 이의용도
WO2010000008A1 (en) 2008-06-30 2010-01-07 Desi Raymond Richardson Thiosemicarbazone compounds and use thereof
CA2725512C (en) 2008-07-18 2016-06-28 F. Hoffmann-La Roche Ag Novel phenylimidazopyrazines
DK200900548A (en) 2008-07-18 2010-01-19 Univ Koebenhavn Processes for manufacture of products from plants

Also Published As

Publication number Publication date
ES2435727T3 (es) 2013-12-23
EP2100614B8 (en) 2013-11-20
KR20080047529A (ko) 2008-05-29
KR101246428B1 (ko) 2013-03-21
KR20090027774A (ko) 2009-03-17
RU2008101772A (ru) 2009-07-27
JP5154470B2 (ja) 2013-02-27
EP2100618A2 (en) 2009-09-16
JP2009102444A (ja) 2009-05-14
BRPI0622074A2 (pt) 2011-07-19
PL2100618T3 (pl) 2014-07-31
EP2100614B1 (en) 2013-10-09
CY2017013I2 (el) 2017-07-12
CA2678008A1 (en) 2006-12-28
CN101612399B (zh) 2013-11-27
BRPI0622073A2 (pt) 2011-07-19
EP2100614A3 (en) 2010-02-17
CN101500597A (zh) 2009-08-05
RU2009115363A (ru) 2010-10-27
JP2009106306A (ja) 2009-05-21
SI2100614T1 (sl) 2014-03-31
CA2678008C (en) 2013-07-30
DK2100618T3 (en) 2014-03-03
EP2100618A3 (en) 2010-06-09
BRPI0611984A2 (pt) 2009-07-07
PT2100614E (pt) 2013-12-16
LUC00012I2 (member.php) 2017-06-19
KR101246504B1 (ko) 2013-03-26
EP2100614A2 (en) 2009-09-16
CA2680945A1 (en) 2006-12-28
US20120034244A1 (en) 2012-02-09
JP2012179060A (ja) 2012-09-20
LTPA2017011I1 (lt) 2017-05-10
WO2006138729A3 (en) 2009-02-12
US20090110678A1 (en) 2009-04-30
LTC2100614I2 (lt) 2018-03-26
EP1909819A4 (en) 2010-02-17
CN101613409A (zh) 2009-12-30
RU2502523C2 (ru) 2013-12-27
RU2009115364A (ru) 2010-10-27
DK2100614T3 (da) 2013-10-28
SI2100618T1 (sl) 2014-03-31
RU2455026C3 (ru) 2020-04-08
KR20090027773A (ko) 2009-03-17
EP2100618B1 (en) 2014-02-12
CA2612449A1 (en) 2006-12-28
US8425911B2 (en) 2013-04-23
CA2680945C (en) 2014-03-18
CN101613409B (zh) 2014-06-04
ES2452115T3 (es) 2014-03-31
PT2100618E (pt) 2014-04-07
CN101612399A (zh) 2009-12-30
JP2009501141A (ja) 2009-01-15
IL198869A (en) 2011-09-27
WO2006138729A2 (en) 2006-12-28
LUC00012I1 (member.php) 2017-04-06
JP5436883B2 (ja) 2014-03-05
HUS1700015I1 (hu) 2017-07-28
PL2100614T3 (pl) 2014-02-28
BRPI0622074A8 (pt) 2017-10-10
CY1114603T1 (el) 2016-10-05
IL198869A0 (en) 2010-02-17
US8574578B2 (en) 2013-11-05
NL300869I2 (nl) 2017-05-24
RU2455026C2 (ru) 2012-07-10
BRPI0622073A8 (pt) 2017-10-03
EP2505205A1 (en) 2012-10-03
US20120027767A1 (en) 2012-02-02
EP1909819A2 (en) 2008-04-16
CY2017013I1 (el) 2017-07-12
IL198870A (en) 2013-03-24
IL198870A0 (en) 2010-02-17
US8128929B2 (en) 2012-03-06
CY1115076T1 (el) 2016-12-14
HK1135917A1 (en) 2010-06-18
BE2017C007I2 (member.php) 2026-02-02

Similar Documents

Publication Publication Date Title
IL188151A0 (en) ANTIBODIES THAT BIND TO HUMAN PDGFRd AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
IL186486A0 (en) Antibodies which bind to gm-csf and pharmaceutical compositions containing the same
IL176749A0 (en) ANTIBODIES TO MAdCAM AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
IL197831A (en) Human antibodies that bind 4cxcr, preparations containing them and their uses
EP2097534A4 (en) HUMAN ANTIBODIES BINDING TO CD70 AND USES THEREOF
IL189876A0 (en) Pharmaceutical formulations containing anti-cd3 antibody
IL199036A0 (en) Human antibodies that bind cd22 and uses thereof
EP2101817A4 (en) CD19 BINDING HUMAN ANTIBODIES AND THEIR USE
HUS1800034I1 (hu) Anti-FGF23 ellenanyag és anti-FGF23 ellenanyagot tartalmazó gyógyászati készítmény
IL186959A0 (en) Peptides and pharmaceutical compositions containing the same
ZA200904657B (en) Human antibodies that bind CD70 and uses thereof
IL197061A (en) Compounds that inhibit the interaction of bcl proteins with binding partners, their medicinal products and their use
IL188941A0 (en) Pyrazinolyguanidine derivatives and pharmaceutical compositions containing the same
IL186738A0 (en) Pyrizole derivatives and pharmaceutical compositions containing the same
IL183919A0 (en) Triazolophthalazine derivatives and pharmaceutical compositions containing the same
IL189782A0 (en) Sulphonylpyrrole derivatives and pharmaceutical compositions containing the same
IL188732A0 (en) Pharmaceutical compositions containing ibuprofen and famotidine
ZA200710496B (en) Antibodies directed to CD20 and used thereof
IL190017A0 (en) Bicyclic compounds and pharmaceutical compositions containing the same
IL178838A (en) Antibodies that specifically bind to human p-psgl-1 and p-selectin, pharmacological preparations containing such antibody, and momentary acids and their encoded vectors
EP1890677A4 (en) PHARMACEUTICAL COMPOSITIONS AND THEIR USE
IL184996A0 (en) Dihydroimidazothiazole derivatives and pharmaceutical compositions containing the same
IL186258A0 (en) Chimeric proteins, their preparation and pharmaceutical compositions containing them
IL177744A0 (en) Aptamers and pharmaceutical compositions containing the same
IL189172A0 (en) Cercosporamide derivatives and pharmaceutical compositions containing the same